TKIs Appear Safe in Patients With Chronic Myeloid Leukemia, CKD

the ONA take:

Tyrosine kinase inhibitors (TKIs) seem safe in patients with chronic myeloid leukemia (CML) in chronic-phase and chronic kidney disease, a recent study published online ahead of print in the journal Cancer has shown.

For the study, researchers investigated the incidence of acute injury and chronic kidney disease in 468 patients with newly diagnosed chronic-phase CML who were treated with imatinib, dasatinib, or nilotinib.

Results showed that 4% of patients experienced TKI-associated acute kidney injury. Researchers found that imatinib was associated with an increased incidence of acute kidney injury compared with dasatinib and nilotinib.

The study also demonstrated that 14% of patients developed chronic kidney disease while receiving TKI treatment. Of those, 84% were receiving imatinib. However, in patients with a history of chronic kidney disease, imatinib did not cause a significant decline in glomerular filtration rate.

"The administration of TKIs may be safe in the setting of CKD in CP CML patients, but close monitoring is still warranted," Musa Yilmaz, M.D., from the Baylor College of Medicine in Houston, TX, and colleagues wrote.

TKIs appear safe in patients with CML and CKD
Tyrosine kinase inhibitors seem safe in patients with chronic myeloid leukemia in chronic-phase and chronic kidney disease.
TKIs appear to be safe in patients with chronic-phase chronic myeloid leukemia and chronic kidney disease, according to a study published online July 28 in Cancer.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs